Autoimmune podocytopathy and anti-nephrin antibodies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter project collects clinical records and available blood and kidney biopsy samples from children and adults diagnosed with podocytopathies such as minimal change disease, FSGS, collapsing glomerulopathy, or diffuse mesangial sclerosis. Laboratory analysis will search for anti-nephrin autoantibodies in serum and renal tissue and link antibody presence to histology, treatment history, and clinical outcomes. The study includes both newly diagnosed patients and those already under follow-up at participating centers, using samples obtained during routine care with informed consent. Findings will be compared across sites to better define the prevalence and clinical significance of anti-nephrin antibodies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pediatric and adult patients with a diagnosis of podocytopathy
* Patients with nephrotic syndrome and/or histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy (CG), or diffuse mesangial sclerosis (DMS)
* Both newly diagnosed (incident) patients and patients already under follow-up at participating centers
* Availability of clinical data from medical records (including paper and/or electronic records, laboratory reports, and discharge summaries)
* Availability of biological samples (e.g., blood and/or renal biopsy), if collected as part of routine clinical care
* Signed informed consent by the patient or legal guardian (and assent when applicable)

Exclusion Criteria:

* Refusal or inability of the patient, parents, or legal guardian to provide informed consent
* Lack of sufficient clinical data or unavailable biological samples required for the study

Where it's running

• Meyer Children's Hospital IRCCS
  Florence, Firenze, Italy Recruiting
• Mayo Clinic
  Rochester, Minnesota, United States Not yet recruiting
• Ludwig-Maximilians Universitat
  München, Germany Not yet recruiting
• Ospedale Santa Maria Annunziata
  Bagno a Ripoli, Firenze, Italy Not yet recruiting
• IRCCS Azienda Ospedaliero - Universitaria
  Bologna, Italy Not yet recruiting
• Azienda Ospedaliero Universitaria Careggi
  Florence, Italy Not yet recruiting

Study contacts

• Study coordinator: Paola Romagnani, MD, PhD
• Email: paola.romagnani@meyer.it
• Phone: +39 0555662563

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exploring experiences of patients and parents dealing with swelling from Nephrotic Syndrome

  This study talks to patients and parents about their experiences with swelling from Nephrotic Syndrome to help create better ways to measure how new treatments work.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT05505500

• Everest001: a medicine for certain kidney diseases to see if it helps adults

  This study tests EVER001 in adults with FSGS, MCD, or IgA nephropathy to see if it can help reduce protein in the urine and improve kidney function.

  Recruiting at 2 sites Phase 2 Everest Medicines (China) Co.,Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07614477

• BAT4406F injection for people with Minimal Change Disease or Focal Segmental Glomerulosclerosis

  BAT4406F injections will be tested to see if they help people with Minimal Change Disease or Focal Segmental Glomerulosclerosis who recently reached remission after corticosteroid treatment.

  Recruiting Phase 2/3 Bio-Thera Solutions · Beijing, Beijing Municipality · NCT07499700

• Using Raman Spectroscopy to Diagnose Kidney Diseases

  This study is testing a new way to diagnose kidney diseases by analyzing urine and blood samples from patients with specific kidney conditions to see if it can help identify the diseases more accurately.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT06760845

• NEPTUNE Match: Personalized matching of patients to kidney treatment options

  This project will try a system that matches people in the NEPTUNE cohort who have nephrotic syndromes or related kidney diseases with suitable clinical trials and shares those matches with patients and their doctors.

  Recruiting at 15 sites University of Michigan · Atlanta, Georgia and 15 other locations · NCT04571658

• Treatment with AP1189 for patients with severe proteinuria due to idiopathic membranous nephropathy

  This study is testing if a new drug called AP1189 can help people with severe proteinuria caused by idiopathic membranous nephropathy feel better when added to their current treatment.

  Recruiting Phase 2 SynAct Pharma Aps · Aarhus · NCT04456816

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.